Packer 2024 — SUMMIT HFpEF Trial

New England Journal of Medicine·September 1, 2024

Packer M, et al.

Summary

Tirzepatide improved health status and exercise capacity, reduced worsening heart failure events in HFpEF patients with obesity.

Study Details

Study Design

Phase 3 randomized, double-blind, placebo-controlled trial

Indication

Heart failure with preserved ejection fraction and obesity

Intervention

Tirzepatide vs placebo

Species

Human

Sample Size

731 subjects